Dutch biotech attracts J&J support for cancer pipeline in $21M Series A
Flindr Therapeutics has secured €20 million ($21 million) in a Series A raise aimed at advancing its lead program through an IND application and growing its pipeline of small-molecule cancer drugs.
The Dutch biotech’s lead drug candidate inhibits RNF31, a protein-stabilizing E3 ubiquitin ligase. The mechanism had “highly promising activity” in preclinical ovarian cancer and B cell lymphoma models, Flindr said, adding it has identified biomarkers that could help identify patients most likely to respond.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.